Advanced pulmonary sarcoidosis.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
3
8
2020
medline:
25
6
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
Mortality in patients with sarcoidosis has primarily been attributed to advanced pulmonary sarcoidosis. This review aims to provide an update on recent clinical studies that help to better phenotype these patients, discuss new treatment options, and suggest areas where additional research is needed. Diagnosis and management of advanced pulmonary sarcoidosis has changed as new technologies and treatment options have emerged. Clinical phenotypes of advanced disease have evolved to show overlap in presentation with other interstitial lung diseases. Assessment involves more advanced imaging modalities. New promising treatment options are being studied. Pulmonary rehabilitation and lung transplantation are being utilized to improve health-related quality of life and survival. Patients with advanced pulmonary fibrosis can have variable clinical, radiographic, histopathologic presentation. Given the poor health-related quality of life and high rates of mortality, medical therapy and pulmonary rehabilitation may benefit these patients. Lung transplantation should be considered in those with end-stage disease.
Identifiants
pubmed: 32740378
doi: 10.1097/MCP.0000000000000705
pii: 00063198-202009000-00028
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
574-581Références
Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 Pt 1):1885–1889.
Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:154–158.
Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38:1368–1373.
Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:1700465.
Sauer WH, Stern BJ, Baughman RP, et al. High-risk sarcoidosis current concepts and research imperatives. Ann Am Thorac Soc 2017; 14: (Suppl_6): S437–S444.
Valeyre D, Nunes H, Bernaudin JF. Advanced pulmonary sarcoidosis. Curr Opin Pulm Med 2014; 20:488–495.
Kouranos V, Wells A, Walsh S. Why do people die from pulmonary sarcoidosis? Curr Opin Pulm Med 2018; 24:527–535.
Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201:e26–e51.
Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149–173.
Akira M. Radiographic differentiation of advanced fibrocystic lung diseases. Ann Am Thorac Soc 2017; 14:432–440.
Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000; 174:1751–1757.
Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013; 107:439–447.
Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med 2013; 107:2009–2013.
Rafferty P, Biggs BA, Crompton GK, Grant IW. What happens to patients with pulmonary aspergilloma? Analysis of 23 cases. Thorax 1983; 38:579–583.
Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest 1987; 92:505–508.
Judson MA. Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns. F1000Res 2019; 8:2149.
Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123–130.
Shigemitsu H, Oblad JM, Sharma OP, Koss MN. Chronic interstitial pneumonitis in end-stage sarcoidosis. Eur Respir J 2010; 35:695–697.
Xu L, Kligerman S, Burke A. End-stage sarcoid lung disease is distinct from usual interstitial pneumonia. Am J Surg Pathol 2013; 37:593–600.
Valeyre D, Bernaudin JF, Jeny F, et al. Pulmonary sarcoidosis. Clin Chest Med 2015; 36:631–641.
Zhang C, Chan KM, Schmidt LA, Myers JL. Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis. Chest 2016; 149:499–507.
Heron M, van Moorsel CH, Grutters JC, et al. Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens 2011; 77:112–117.
Sato H, Williams HR, Spagnolo P, et al. CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. Eur Respir J 2010; 35:324–330.
Hill MR, Papafili A, Booth H, et al. Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis. Am J Respir Crit Care Med 2006; 174:915–922.
Kruit A, Grutters JC, Ruven HJ, et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006; 129:1584–1591.
Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68:436–441.
Collins BF, McClelland RL, Ho LA, et al. Sarcoidosis and IPF in the same patient – a coincidence, an association or a phenotype? Respir Med 2018; 144S:S20–S27.
Uzunhan Y, Nunes H, Jeny F, et al. Chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2017; 49:1602396.
Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47:45–68.
Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:433–442.
Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest 2018; 153:105–113.
Jeny F, Uzunhan Y, Lacroix M, et al. Predictors of mortality in fibrosing pulmonary sarcoidosis. Respir Med 2020; 169:105997.
Kinloch AJ, Kaiser Y, Wolfgeher D, et al. In situ humoral immunity to vimentin in HLA-DRB1∗03(+) patients with pulmonary sarcoidosis. Front Immunol 2018; 9:1516.
Vihlborg P, Bryngelsson IL, Andersson L, Graff P. Risk of sarcoidosis and seropositive rheumatoid arthritis from occupational silica exposure in Swedish iron foundries: a retrospective cohort study. BMJ Open 2017; 7:e016839.
Beijer E, Meek B, Kromhout H, et al. Sarcoidosis in a patient clinically diagnosed with silicosis; is silica associated sarcoidosis a new phenotype? Respir Med Case Rep 2019; 28:100906.
Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795–802.
Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med 2014; 108:189–194.
Thery-Casari JY, Bouvry D, Chapelon-Abric C, et al. Outcome of patients with sarcoidosis refractory to TNF antagonists: a case series. Sarcoidosis Vasc Diffuse Lung Dis 2018; 35:371–375.
El Jammal T, Jamilloux Y, Gerfaud-Valentin M, et al. Refractory sarcoidosis: a review. Ther Clin Risk Manag 2020; 16:323–345.
Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 2014; 43:1525–1528.
Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy 2015; 13:19.
Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X 2019; 1:100004.
Rotenberg C, Besnard V, Brillet PY, et al. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J 2018; 52:1801482.
Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung 2017; 195:313–322.
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381:1718–1727.
Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8:453–460.
Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 2017; 132:9–14.
Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and forced vital capacity change in newly-treated pulmonary sarcoidosis. Respir Med 2018; 138s:S31–S37.
Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104:717–723.
Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med 2011; 184:159–171.
Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report – 2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019; 38:1042–1055.
Taimeh Z, Hertz MI, Shumway S, Pritzker M. Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. Thorax 2016; 71:378–379.
Hong A, King CS, Brown AW, et al. Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidiscip Respir Med 2016; 11:40.
Manzia TM, Bellini MI, Corona L, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of Rapamune after liver transplantation. Transpl Int 2011; 24:e69–e70.
Linke M, Pham HT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol 2017; 18:293–302.
Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial. J Cardiopulm Rehabil Prev 2018; 38:124–130.
Strookappe B, Elfferich M, Swigris J, et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32:43–52.
Lingner H, Buhr-Schinner H, Hummel S, et al. Short-term effects of a multimodal 3-week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study. Respiration 2018; 95:343–353.
Pitta F, Troosters T, Probst VS, et al. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J 2006; 27:1040–1055.
Froidure S, Kyheng M, Grosbois JM, et al. Daily life physical activity in patients with chronic stage IV sarcoidosis: a multicenter cohort study. Health Sci Rep 2019; 2:e109.
Pacheco Y, Lim CX, Weichhart T, et al. Sarcoidosis and the mTOR, Rac1, and autophagy triad. Trends Immunol 2020; 41:286–299.
Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3:349–363.
Blaauboer ME, Smit TH, Hanemaaijer R, et al. Cyclic mechanical stretch reduces myofibroblast differentiation of primary lung fibroblasts. Biochem Biophys Res Commun 2011; 404:23–27.